Laerdal Medical recalled 1,202 Compact Suction Units on January 13, 2026. The recall affects models LCSU 4, 800 ml and LCSU 4, 300 ml due to excessive electromagnetic noise. Patients and healthcare providers must stop using the devices immediately.
units manufactured in a limited time period may emit electromagnetic noise beyond the acceptable limits for RTCA application specified in RTCA DO-160G Chapter 21, Equipment Category M.
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact Laerdal Medical Corporation or your healthcare provider for instructions. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recalled models are LCSU 4, 800 ml (Catalog Number: 880052), LCSU 4, 300 ml (Catalog Number: 880062), and LCSU 4 (Catalog Number: 881152). These units were distributed worldwide, including the US, Denmark, Sweden, Norway, Canada, Finland, Australia, and several European countries. The devices were sold from 2021 to 2026.
These suction units may emit electromagnetic noise that exceeds allowable limits set by RTCA DO-160G Chapter 21, Equipment Category M. This could interfere with other medical devices, posing a risk to patient safety.
No injuries or incidents have been reported due to this issue. The recall is precautionary to ensure patient safety.
Stop using the recalled suction units immediately. Contact Laerdal Medical Corporation or your healthcare provider for instructions on returning the devices.
For more information, contact Laerdal Medical Corporation at their website or via phone. Detailed recall instructions are available through the FDA link.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.